Hyperbaric oxygen therapy for acute coronary syndrome

Area of Science:

• Cardiology
• Hyperbaric Medicine
• Critical Care

Background:

• Acute coronary syndrome (ACS) is a life-threatening condition requiring effective treatments.
• Hyperbaric oxygen therapy (HBOT) enhances oxygen supply to ischemic tissues.
• Adjunctive HBOT may improve outcomes in ACS by reducing myocardial damage and mortality.

Purpose of the Study:

• To evaluate the efficacy and safety of adding hyperbaric oxygen therapy (HBOT) to standard treatments for acute coronary syndrome (ACS).
• To assess the impact of HBOT on mortality, myocardial damage, and other major adverse cardiovascular events in ACS patients.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs) comparing HBOT plus standard care versus standard care alone for ACS.
• Comprehensive literature search across multiple databases (CENTRAL, MEDLINE, EMBASE, etc.) updated to June 2010.
• Independent quality assessment and data extraction by three reviewers following Cochrane guidelines.

Main Results:

• Six trials with 665 participants indicated a significant reduction in mortality risk with HBOT (RR 0.58).
• HBOT was associated with reduced myocardial damage, evidenced by lower cardiac enzyme levels and improved left ventricular ejection fraction (LVEF).
• Individual trials suggested benefits including reduced risk of major adverse coronary events (MACE), re-infarction, dysrhythmias, and faster pain relief.

Conclusions:

• Preliminary evidence from small trials suggests HBOT may reduce mortality, myocardial damage, MACE, and ischemic pain in ACS patients.
• Caution is advised due to trial limitations (small sample size, methodological issues, poor reporting).
• High-quality, adequately powered trials are necessary to confirm HBOT's benefits and identify patient subgroups who may benefit most; routine use is not yet justified.